Shareholder Alert: Ademi LLP investigates whether Pardes Biosciences, Inc. has obtained a Fair Price in its transaction with MediPacific

MILWAUKEE, July 17, 2023 /PRNewswire/ — Ademi LLP is investigating Pardes (Nasdaq: PRDS) for possible breaches of fiduciary duty and other violations of law in its transaction with MediPacific. Click here to learn how to join the action…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.